A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

This study is for people with Type 2 Diabetes, a condition where the body doesn't use insulin properly. It compares two treatments: semaglutide with a lower dose of insulin glargine, and a higher dose of insulin glargine alone. Insulin glargine is a type of insulin that helps manage blood sugar. Semaglutide is a medicine that helps lower blood sugar. The study lasts about 11 months with 9 clinic visits, 15 phone/video calls, and 1 home visit. Participants will use a special sensor to track their blood sugar for two 10-day periods. To join, you need to have been diagnosed with Type 2 Diabetes for at least 180 days, have a certain level of blood sugar (HbA1c), and a specific body mass index (BMI). You should also be on a stable dose of diabetes medications. Some people cannot join if they have other health issues like uncontrolled eye problems or a history of pancreatitis.

• Duration: 47 weeks with several visits and calls.
• Participants will use a sensor to monitor blood sugar.
• Involves two different diabetes treatments.